Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Employees

511

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 02:30:00 27/02/2026 am IST			5-day change	1st Jan Change
72.82 ^USD	+0.03%		-.--%	+0.96%

03/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Global BMI Index	CI
03/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Biotechnology Select Industry Index	CI

Capitalization	1.13TCr 970.16Cr 876.97Cr 839.67Cr 1.53TCr 1,03800Cr 1.58TCr 10TCr 4.14TCr 50TCr 4.24TCr 4.15TCr 1,78100Cr	P/E ratio 2026 *	-14.3x	P/E ratio 2027 *	-20.3x
Enterprise value	1.06TCr 911.04Cr 823.54Cr 788.5Cr 1.44TCr 97TCr 1.49TCr 9.7TCr 3.88TCr 47TCr 3.98TCr 3.9TCr 1,67300Cr	EV / Sales 2026 *	773x	EV / Sales 2027 *	27.2x
Free-Float	95.17%	Yield 2026 *	-	Yield 2027 *	-

03/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Global BMI Index	CI
03/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Biotechnology Select Industry Index	CI
03/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P TMI Index	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell Small Cap Comp Growth Benchmark	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 3000E Growth Benchmark	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 3000 Growth Benchmark	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Growth Benchmark	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Growth Benchmark	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Value-Dynamic Index	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Growth-Dynamic Index	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Value-Dynamic Index	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Growth-Dynamic Index	CI
02/03	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Dynamic Index	CI

18/12	Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65	MT
10/12	Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says	MT
07/11	Chardan Downgrades Avidity Biosciences to Neutral From Buy	MT
29/25/29	Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform	MT
29/25/29	TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78	MT

Avidity Biosciences, Inc. Share Price

Equities

RNA

US05370A1088

Pharmaceuticals

Valuation: Avidity Biosciences, Inc.

Chart: Avidity Biosciences, Inc.

Latest news: Avidity Biosciences, Inc.

Last Transcript: Avidity Biosciences, Inc.

Analysts' recommendations: Avidity Biosciences, Inc.

Press Releases: Avidity Biosciences, Inc.

News in other languages: Avidity Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avidity Biosciences, Inc.

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

02/03	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	AQ
02/03	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	AQ
27/02	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	PR
27/02	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	PR
23/02	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders	PR

27/02	Bourse Zurich: le SMI finit en forme grâce aux poids lourds
27/02	Novartis finalise l'acquisition d'Avidity Biosciences
27/02	Novartis schliesst Übernahme von Avidity Biosciences ab
04/02	Größter Patentverlust seit Jahren: Novartis stellt sich auf Gewinnrückgang ein
03/02	Prévisions Novartis: à l'aube de pertes d'exclusivité

1 day	+0.03%
1 month	-0.10%
3 months	+2.06%
6 months	+56.94%
Current year	+0.96%

1 month	72.68	73.05
Current year	72	73.06
1 year	21.51	73.06
3 years	4.82	73.06
5 years	4.82	73.06
10 years	4.82	73.06

Manager	Title	Age	Since
John McKenna PSD	President	-	27/02/2026
Jaime S. Huertas SEC	Corporate Secretary	-	27/02/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AVIDITY BIOSCIENCES, INC.	+0.03%	-.--%	+142.41%	+254.70%	1.13TCr
REGENERON PHARMACEUTICALS, INC.	-1.22%	+0.70%	+3.65%	+3.35%	8.02TCr
UCB	+2.69%	+4.11%	+55.43%	+228.22%	5.66TCr
SAMSUNG BIOLOGICS CO.,LTD.	+0.82%	+59.20%	+59.20%	+59.20%	4.95TCr
CSL LIMITED	-1.36%	-1.96%	-44.24%	-50.22%	4.82TCr
BIOGEN INC.	+0.09%	+2.39%	+25.01%	-26.56%	2.76TCr
MODERNA, INC.	-1.36%	+10.34%	+52.89%	-60.24%	2.2TCr
INCYTE CORPORATION	-1.11%	-2.09%	+34.99%	+33.34%	1.93TCr
INNOVENT BIOLOGICS, INC.	+4.95%	+3.87%	+113.43%	+115.04%	1.81TCr
SWEDISH ORPHAN BIOVITRUM AB	+3.41%	+0.05%	+32.00%	+60.64%	1.41TCr
Average	+0.68%	+0.14%	+47.48%	+61.75%	3.47TCr
Weighted average by Cap.	+0.32%	+0.41%	+31.34%	+52.14%

	2026 *	2027 *
Net sales	1.37Cr 1.18Cr 1.06Cr 1.02Cr 1.86Cr 126Cr 1.92Cr 13Cr 5.02Cr 60Cr 5.15Cr 5.04Cr 216.29Cr	40Cr 34Cr 31Cr 29Cr 54Cr 3.63TCr 55Cr 361.28Cr 144.67Cr 1.74TCr 148.32Cr 145.17Cr 6.23TCr
Net income	-84Cr -72Cr -65Cr -63Cr -114.44Cr -7.74TCr -118.05Cr -770.74Cr -308.63Cr -3.71TCr -316.41Cr -309.69Cr -13TCr	-60Cr -52Cr -47Cr -45Cr -82Cr -5.53TCr -84Cr -550.13Cr -220.29Cr -2.65TCr -225.84Cr -221.05Cr -9.49TCr
Net Debt	-69Cr -59Cr -53Cr -51Cr -93Cr -6.32TCr -96Cr -629.38Cr -252.02Cr -3.03TCr -258.38Cr -252.89Cr -11TCr	-57Cr -49Cr -44Cr -42Cr -77Cr -5.21TCr -79Cr -518.24Cr -207.52Cr -2.5TCr -212.75Cr -208.23Cr -8.94TCr